Literature DB >> 22302946

Comparison of benzodiazepine (BZ) receptor agonists in two rodent activity tests.

P J Bayley1, G D Bentley, A Jackson, D Williamson, G R Dawson.   

Abstract

The effects of four BZ receptor ligands in an operant test were compared with a rotarod test. In the operant test, rats were trained to pull a chain on a schedule that regulates the probability of delivery of food pellets to maintain a steady chain-pulling rate across a 1 h test session. For the rotarod test, mice were trained to remain on a rotarod for 2 min. Diazepam (0.1-3.0 mg/kg, i.p.), FG 8205 (0.1-3.0 mg/kg, i.p.), quazepam (3.0-60.0 mg/kg, i.p.) and zolpidem (0.3-10.0 mg/kg, i.p.) each produced dose-related impairments of performance in both the chain- pulling test and the mouse rotarod test. Furthermore, the impairment in performance induced by FG 8205 (10.0 mg/kg, p.o.) was dose-dependently reversed by the BZ receptor antagonist, flumazenil (1.0-10.0 mg/kg, i.p.), indicating that the chain-pulling deficit was mediated via BZ receptor activation. Diazepam, FG 8205 and quazepam all had comparable potencies in both the rotarod assay and the chain-pulling test. However, zolpidem suppressed the chain-pulling rates at a dose 30-fold lower than that required to induce a significant deficit in the rotarod performance. As zolpidem is a preferentially sedative compound, this pattern of results is consistent with the hypothesis that the chain-pulling test is sensitive to sedation induced by BZ receptor agonists.

Entities:  

Year:  1996        PMID: 22302946     DOI: 10.1177/026988119601000305

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  2 in total

1.  Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptors.

Authors:  John R Atack; Peter H Hutson; Neil Collinson; George Marshall; Graham Bentley; Christopher Moyes; Susan M Cook; Ian Collins; Keith Wafford; Ruth M McKernan; Gerard R Dawson
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

2.  Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865.

Authors:  Sarah A Nickolls; Rachel Gurrell; Guido van Amerongen; Juha Kammonen; Lishuang Cao; Adam R Brown; Clara Stead; Andy Mead; Christine Watson; Cathleen Hsu; Robert M Owen; Andy Pike; Rebecca L Fish; Laigao Chen; Ruolun Qiu; Evan D Morris; Gang Feng; Mark Whitlock; Donal Gorman; Joop van Gerven; David S Reynolds; Pinky Dua; Richard P Butt
Journal:  Br J Pharmacol       Date:  2018-01-18       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.